289 related articles for article (PubMed ID: 28178648)
1. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Kuo SH; Yang SY; You SL; Lien HC; Lin CH; Lin PH; Huang CS
Oncotarget; 2017 Mar; 8(13):20925-20938. PubMed ID: 28178648
[TBL] [Abstract][Full Text] [Related]
2. Association of Estrogen Receptor Alpha and Interleukin 6 Polymorphisms with Lymphovascular Invasion, Extranodal Extension, and Lower Disease-Free Survival in Thai Breast Cancer Patients.
Sa-Nguanraksa D; Suntiparpluacha M; Kulprom A; Kummalue T; Chuangsuwanich T; Avirutnan P; O-Charoenrat P
Asian Pac J Cancer Prev; 2016; 17(6):2935-40. PubMed ID: 27356714
[TBL] [Abstract][Full Text] [Related]
3. CYP19 genetic polymorphism haplotype AASA is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer.
Kuo SH; Yang SY; Lien HC; Lo C; Lin CH; Lu YS; Cheng AL; Chang KJ; Huang CS
Biomed Res Int; 2013; 2013():562197. PubMed ID: 24324964
[TBL] [Abstract][Full Text] [Related]
4. CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.
Tüzüner BM; Oztürk T; Kisakesen HI; Ilvan S; Zerrin C; Oztürk O; Isbir T
In Vivo; 2010; 24(1):71-4. PubMed ID: 20133979
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor alpha polymorphisms: correlation with clinicopathological parameters in breast cancer.
Anghel A; Raica M; Narita D; Seclaman E; Nicola T; Ursoniu S; Anghel M; Popovici E
Neoplasma; 2010; 57(4):306-15. PubMed ID: 20429621
[TBL] [Abstract][Full Text] [Related]
6. Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer.
Udler MS; Azzato EM; Healey CS; Ahmed S; Pooley KA; Greenberg D; Shah M; Teschendorff AE; Caldas C; Dunning AM; Ostrander EA; Caporaso NE; Easton D; Pharoah PD
Int J Cancer; 2009 Dec; 125(11):2687-96. PubMed ID: 19551860
[TBL] [Abstract][Full Text] [Related]
7. Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians.
Shan J; Mahfoudh W; Dsouza SP; Hassen E; Bouaouina N; Abdelhak S; Benhadjayed A; Memmi H; Mathew RA; Aigha II; Gabbouj S; Remadi Y; Chouchane L
Breast Cancer Res Treat; 2012 Oct; 135(3):715-24. PubMed ID: 22910930
[TBL] [Abstract][Full Text] [Related]
8. Identification of Novel Breast Cancer Risk Loci.
Chan CHT; Munusamy P; Loke SY; Koh GL; Wong ESY; Law HY; Yoon CS; Tan MH; Yap YS; Ang P; Lee ASG
Cancer Res; 2017 Oct; 77(19):5428-5437. PubMed ID: 28775167
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
10. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.
Rebbeck TR; DeMichele A; Tran TV; Panossian S; Bunin GR; Troxel AB; Strom BL
Carcinogenesis; 2009 Feb; 30(2):269-74. PubMed ID: 19028704
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients.
Markiewicz A; Wełnicka-Jaśkiewicz M; Skokowski J; Jaśkiewicz J; Szade J; Jassem J; Zaczek AJ
PLoS One; 2013; 8(8):e72219. PubMed ID: 23951298
[TBL] [Abstract][Full Text] [Related]
12. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
[TBL] [Abstract][Full Text] [Related]
13. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
Chen X; Li Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2018 Oct; 29(10):2046-2051. PubMed ID: 30165555
[TBL] [Abstract][Full Text] [Related]
14. MAP3K1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer.
Kuo SH; Wei MF; Lee YH; Lin JC; Yang WC; Yang SY; Huang CS
Cell Oncol (Dordr); 2023 Oct; 46(5):1213-1234. PubMed ID: 37166744
[TBL] [Abstract][Full Text] [Related]
15. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer.
Stacey SN; Manolescu A; Sulem P; Thorlacius S; Gudjonsson SA; Jonsson GF; Jakobsdottir M; Bergthorsson JT; Gudmundsson J; Aben KK; Strobbe LJ; Swinkels DW; van Engelenburg KC; Henderson BE; Kolonel LN; Le Marchand L; Millastre E; Andres R; Saez B; Lambea J; Godino J; Polo E; Tres A; Picelli S; Rantala J; Margolin S; Jonsson T; Sigurdsson H; Jonsdottir T; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Sveinsdottir SG; Alexiusdottir K; Saemundsdottir J; Sigurdsson A; Kostic J; Gudmundsson L; Kristjansson K; Masson G; Fackenthal JD; Adebamowo C; Ogundiran T; Olopade OI; Haiman CA; Lindblom A; Mayordomo JI; Kiemeney LA; Gulcher JR; Rafnar T; Thorsteinsdottir U; Johannsson OT; Kong A; Stefansson K
Nat Genet; 2008 Jun; 40(6):703-6. PubMed ID: 18438407
[TBL] [Abstract][Full Text] [Related]
16. Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women.
Zhang L; Gu L; Qian B; Hao X; Zhang W; Wei Q; Chen K
Breast Cancer Res Treat; 2009 Mar; 114(2):327-38. PubMed ID: 18629629
[TBL] [Abstract][Full Text] [Related]
17. Association of breast cancer susceptibility variants with risk of pancreatic cancer.
Couch FJ; Wang X; McWilliams RR; Bamlet WR; de Andrade M; Petersen GM
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3044-8. PubMed ID: 19843670
[TBL] [Abstract][Full Text] [Related]
18. Association of single nucleotide polymorphisms in FGF-RAS/MAP signalling cascade with breast cancer susceptibility.
Dankova Z; Zubor P; Grendar M; Kapinova A; Zelinova K; Jagelkova M; Gondova A; Dokus K; Kalman M; Lasabova Z; Danko J
Gen Physiol Biophys; 2017 Dec; 36(5):565-572. PubMed ID: 29372690
[TBL] [Abstract][Full Text] [Related]
19. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Fasching PA; Loehberg CR; Strissel PL; Lux MP; Bani MR; Schrauder M; Geiler S; Ringleff K; Oeser S; Weihbrecht S; Schulz-Wendtland R; Hartmann A; Beckmann MW; Strick R
Breast Cancer Res Treat; 2008 Nov; 112(1):89-98. PubMed ID: 18049890
[TBL] [Abstract][Full Text] [Related]
20. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N
BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
